Negotiation on the price of Onureg has started

Pay attention to whether there is an agreement

Passed by the Pharmaceutical Evaluation Committee in April of last year

Suggestion of treatment options for patients unable to undergo hematopoietic stem cell transplantation Onureg, an acute myelogenous leukemia maintenance treatment drug, recently entered into drug price negotiations for insurance coverage.

 

After passing the HIRA Cancer Disease Review Committee in December of last year and the Pharmaceutical Reimbursement Evaluation Committee last month, it entered the NHIS procedure without any major changes.

 

Considering the deadline for negotiations, the results are expected to come out in June at the latest.

 

Onureg was approved on March 23, 2022, for maintenance therapy in adult patients with acute myeloid leukemia who achieved CR or CRi with incomplete hematologic recovery after induction therapy, with or without consolidation therapy, and who are not suitable for HSCT.

 

Whether Oneurec can be recognized for its clinical value as the first and only treatment option that clinically extends the survival period for AML patients who cannot undergo hematopoietic stem cell transplantation and who have failed to extend their overall survival despite several R&D attempts over the years.

 

Onureg confirmed efficacy and safety in phase 3 of QUAZAR AML-001 in 472 patients with acute myeloid leukemia.

 

As a result of the study, the mOS of the patient group who took Onureg was 24.7 months, extending the survival time by about 10 months compared to 14.8 months of the placebo group.

 

At 1 year and 2 years of treatment, the survival rate in the Onureg group was 73% (vs.

 

56% vs.

 

placebo group) and 51% (vs.

 

37% vs.

 

placebo group), respectively, both higher than those in the placebo group.

 

RFS also confirmed that the Onureg group reached 10.2 months, 5.4 months longer than the placebo group (4.8 months), reducing the risk of recurrence.

 

The proportion of patients without recurrence after 6 months of treatment was 67% in the Onureg group and 45% in the placebo group.

 

Onureg has been recognized for its clinical usefulness in major overseas countries such as the UK and Australia and is being recommended for reimbursement to patients to be treated.